Latest Market News

Pinnacle Investment Management reported an 11% drop in net profit after tax for the first half of FY26, despite record net inflows and a strategic move to fully acquire Pacific Asset Management.

Pinnacle Investment Management reported a solid 13% increase in funds under management to $202.5 billion despite an 11% drop in half-year profit. The company declared a 29 cent interim dividend and advanced its international expansion with key acquisitions.

Pinnacle Investment Management reported a robust 66.6% increase in revenues for the half year ended December 2025, yet profits and earnings per share declined, prompting a cautious outlook despite a healthy interim dividend.

CVC Limited forecasts a substantial increase in its half-year net loss, prompting the board to suspend the interim dividend amid cashflow concerns.

The Federal Court of Australia has approved the acquisition schemes for Global Uranium and Enrichment Limited by Snow Lake Resources, setting the stage for a significant shift in shareholder structure and market listing.

Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

St George Mining has released a comprehensive investor presentation spotlighting its Araxá Project in Brazil, positioning itself as a major global player in niobium and rare earth elements with significant resource expansion and strategic partnerships underway.

The Federal Court of Australia has approved Caterpillar’s acquisition of mining software leader RPMGlobal, paving the way for a $5 per share payout to shareholders and a pending ASX trading halt.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.